Patents by Inventor Anthony Mazurek

Anthony Mazurek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Automated electrical charger for autonomous platforms
    Patent number: 9973014
    Abstract: A system for charging rechargeable devices. A landing surface includes a plurality of conductive patches, and a rechargeable device includes a plurality of contacts. The configurations of the conductive patches and of the contacts are selected to establish, when the contacts of the rechargeable device come into contact with the landing surface, a plurality of separate conductive paths between a charger and the rechargeable device.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 15, 2018
    Assignee: RAYTHEON BBN TECHNOLOGIES, INC.
    Inventors: Edin Insanic, Joshua Cochin, Kyle Francis Usbeck, Jeffrey Anthony Mazurek
  • AUTOMATED ELECTRICAL CHARGER FOR AUTONOMOUS PLATFORMS
    Publication number: 20170244263
    Abstract: A system for charging rechargeable devices. A landing surface includes a plurality of conductive patches, and a rechargeable device includes a plurality of contacts. The configurations of the conductive patches and of the contacts are selected to establish, when the contacts of the rechargeable device come into contact with the landing surface, a plurality of separate conductive paths between a charger and the rechargeable device.
    Type: Application
    Filed: September 29, 2016
    Publication date: August 24, 2017
    Inventors: Edin Insanic, Joshua Cochin, Kyle Francis Usbeck, Jeffrey Anthony Mazurek
  • IDENTIFICATION OF RNAI TARGETS AND USE OF RNAI FOR RATIONAL THERAPY OF CHEMOTHERAPY-RESISTANT LEUKEMIA AND OTHER CANCERS
    Publication number: 20150283101
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Application
    Filed: November 3, 2014
    Publication date: October 8, 2015
    Inventors: Bruce STILLMAN, Scott W. LOWE, Anthony MAZUREK, Johannes Ekkehart ZUBER, Christopher VAKOC, Katherine MCJUNKIN
  • Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
    Patent number: 8895526
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: November 25, 2014
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Bruce Stillman, Scott W. Lowe, Anthony Mazurek, Johannes Ekkehart Zuber, Christopher Vakoc, Katherine McJunkin
  • IDENTIFICATION OF RNAI TARGETS AND USE OF RNAI FOR RATIONAL THERAPY OF CHEMOTHERAPY-RESISTANT LEUKEMIA AND OTHER CANCERS
    Publication number: 20120272346
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Application
    Filed: March 29, 2010
    Publication date: October 25, 2012
    Inventors: Bruce Stillman, Scott W. Lowe, Anthony Mazurek, Johannes Ekkehart Zuber, Christopher Vakoc, Katherine McJunkin